Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

23ANDME HOLDING CO.

(ME)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
8.22(c) 7.54(c) 8(c) 7.65(c) 7.91 Last
5 621 697 2 640 771 2 741 976 3 429 225 1 828 091 Volume
-7.12% -8.27% +6.10% -4.38% +3.40% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 258 M - -
Net income 2022 -184 M - -
Net cash position 2022 566 M - -
P/E ratio 2022 -14,4x
Yield 2022 -
Sales 2023 313 M - -
Net income 2023 -208 M - -
Net cash position 2023 413 M - -
P/E ratio 2023 -15,3x
Yield 2023 -
Capitalization 3 347 M 3 347 M -
EV / Sales 2022 10,8x
EV / Sales 2023 9,37x
Nbr of Employees 500
Free-Float 12,3%
More Financials
Company
23andMe Holding Co., formerly VG Acquisition Corp., is a consumer genetics and research company. The Company offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The Company operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and... 
More about the company
All news about 23ANDME HOLDING CO.
12/0123ANDME : New 23andMe Health Service is FSA & HSA Eligible
PU
11/3023andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific O..
GL
11/3023AndMe Holding Co. Appoints Joseph R. Arron as Chief Scientific Officer
CI
11/30Sapphire Ventures raises $2 bln in latest capital raise
RE
11/2223ANDME : Announces Redemption of All Outstanding Warrants - Form 8-K
PU
11/2223ANDME HOLDING CO. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/2223andMe Announces Redemption of All Outstanding Warrants
AQ
11/1523ANDME : Understanding Opioid Use Disorder
PU
11/15Citigroup Downgrades 23andMe to Neutral From Buy, Adjusts Price Target to $13 From $12
MT
11/10Recent addition of telemedicine platform further advances vision of individualized prim..
PU
11/1023ANDME HOLDING CO. Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/1023andMe Holding Seeks Acquisitions
CI
11/10Earnings Flash (ME) 23ANDME HOLDING CO. Reports Q2 Revenue $55.2M, vs. Street Est of $5..
MT
11/1023andMe Reports FY2022 Second Quarter Financial Results
GL
11/1023andMe Reports FY2022 Second Quarter Financial Results
GL
More news
News in other languages on 23ANDME HOLDING CO.
11/10Earnings Flash (ME) 23ANDME HOLDING CO. annonce un chiffre d'affaires de 55,2 millions ..
11/1023andMe Holding Co. met à jour ses prévisions de bénéfices pour 2022
10/22Les actions du secteur de la santé en hausse près de la clôture de vendredi
10/2223andMe va acquérir la plateforme de télémédecine Lemonaid Health pour développer son a..
10/2223andMe rachète l'entreprise de télésanté Lemonaid pour 400 millions de dollars.
More news
Analyst Recommendations on 23ANDME HOLDING CO.
More recommendations
Chart 23ANDME HOLDING CO.
Duration : Period :
23andMe Holding Co. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 23ANDME HOLDING CO.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 7,65 $
Average target price 13,50 $
Spread / Average Target 76,5%
EPS Revisions
Managers and Directors
Anne E. Wojcicki Chief Executive Officer & Director
Steven Schoch Chief Financial & Accounting Officer
Steve Lemon Vice President-Engineering
Joyce Tung Vice President-Research
L. Okey Onyejekwe VP-Healthcare Operations & Medical Affairs
Sector and Competitors